Ulcerative Colitis – Pipeline Review, 2019

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

<p><b>1. Introduction</b></p><p>    1.1. Report Overview</p><p><b>2. Ulcerative colitis - Overview</b></p><p><b>3. Executive Summary</b></p><p><b>4. Ulcerative colitis: Pipeline Assessment</b></p><p>    4.1. By Stage of Development</p><p>    4.2. By Route of Administration</p><p>    4.3. By Drug Class</p><p>    4.4. By Molecule Type</p><p>    4.5. By Therapy Area / Indication</p><p>    4.6. By Drug Target</p><p>    4.7. By Sponsor</p><p><b>5. Ulcerative colitis: Company & Drug Profiles</b></p><p>    5.1. Clinical Stage</p><p>        5.1.1. SHP647 – Shire</p><p>            5.1.1.1. Company Overview</p><p>            5.1.1.2. Product Description</p><p>            5.1.1.3. R&D Status & Development Activities</p><p>            5.1.1.4. Mechanism of Action</p><p>            5.1.1.5. Molecule Type</p><p>            5.1.1.6. Stage of Development</p><p>            5.1.1.7. Indications</p><p>            5.1.1.8. Route of Administration</p><p>            5.1.1.9. Funding</p><p>        5.1.2. RO7049665 – F. Hoffmann-La Roche Ltd</p><p>            5.1.2.1. Company Overview</p><p>            5.1.2.2. Product Description</p><p>            5.1.2.3. R&D Status & Development Activities</p><p>            5.1.2.4. Mechanism of Action</p><p>            5.1.2.5. Molecule Type</p><p>            5.1.2.6. Stage of Development</p><p>            5.1.2.7. Indications</p><p>            5.1.2.8. Route of Administration</p><p>            5.1.2.9. Funding</p><p>        5.1.3. RPC1063– CELGENE CORPORATION</p><p>            5.1.3.1. Company Overview</p><p>            5.1.3.2. Product Description</p><p>            5.1.3.3. R&D Status & Development Activities</p><p>            5.1.3.4. Mechanism of Action</p><p>            5.1.3.5. Molecule Type</p><p>            5.1.3.6. Stage of Development</p><p>            5.1.3.7. Indications</p><p>            5.1.3.8. Route of Administration</p><p>            5.1.3.9. Funding</p><p>        5.1.4. Others</p><p>    5.2. Preclinical</p><p>        5.2.1. Company Overview</p><p>        5.2.2. Product Description</p><p>        5.2.3. R&D Status & Development Activities</p><p>        5.2.4. Mechanism of Action</p><p>        5.2.5. Molecule Type</p><p>        5.2.6. Indications</p><p>        5.2.7. Route of Administration</p><p>        5.2.8. Funding</p><p><b>6. Ulcerative colitis: An Overview on Dormant & Discontinued Pipeline Candidates</b></p><p>    6.1. Overview</p><p>    6.2. Product Description</p><p>    6.3. Reason for Discontinuation</p><p><b>7. Ulcerative colitis: Additional Key Insights</b></p><p>    7.1. Epidemiology Overview: Ulcerative Colitis</p><p>    7.2. Current Treatment Overview: Ulcerative Colitis</p><p><b>8. Ulcerative colitis: News, Press Releases and Conference Details</b></p>

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.